key: cord-0767735-cgwu2ncv
authors: Umpierrez, Guillermo; Rushakoff, Robert; Seley, Jane Jeffrie; Zhang, Jennifer Y.; Shang, Trisha; Han, Julia; Spanakis, Elias K.; Alexanian, Sara; Drincic, Andjela; Kulasa, Kristen; Mendez, Carlos E.; Tanton, Damon; Wallia, Amisha; Zilbermint, Mihail; Klonoff, David C.
title: Hospital Diabetes Meeting 2020
date: 2020-08-12
journal: J Diabetes Sci Technol
DOI: 10.1177/1932296820939626
sha: 386b9e06d83536f0515ebc52de7afe0bc587f271
doc_id: 767735
cord_uid: cgwu2ncv

Patients with diabetes may experience adverse outcomes related to their glycemic control when hospitalized. Continuous glucose monitoring systems, insulin-dosing software, enhancements to the electronic health record, and other medical technologies are now available to improve hospital care. Because of these developments, new approaches are needed to incorporate evolving treatments into routine care. With the goal of educating healthcare professionals on the most recent practices and research for managing diabetes in the hospital, Diabetes Technology Society hosted the Virtual Hospital Diabetes Meeting on April 24-25, 2020. Because of the coronavirus disease 2019 (COVID-19) pandemic, the meeting was restructured to be held virtually during the national lockdown to ensure the safety of the participants and allow them to remain at their posts treating COVID-19 patients. The meeting focused on (1) inpatient management and perioperative care, (2) diabetic ketoacidosis and hyperglycemic hyperosmolar state, (3) computer-guided insulin dosing, (4) Coronavirus Disease 2019 and diabetes, (5) technology, (6) hypoglycemia, (7) data and cybersecurity, (8) special situations, (9) glucometrics and insulinometrics, and (10) quality and safety. This meeting report contains summaries of each of the ten sessions. A virtual poster session will be presented within two months of the meeting.

Key ideas • • Insulin is the most effective and most well-studied medication for the treatment of diabetes and hyperglycemia in the inpatient setting. • • Although it may cause hypoglycemia and may require increased nursing time and frequent dose adjustments from users who are trained in this type of management, the benefits are well worth its use. • • Better control has been noted in both medical and surgical patients with diabetes and/or hyperglycemia utilizing a weight-based basal, bolus, and supplemental regimen.

Summary. Insulin therapy is the recommended approach for the management of hospitalized patients with diabetes or hyperglycemia. Subcutaneous insulin administration following a basal-bolus or a basal-plus regimen is the favored strategy for noncritically ill hospitalized patients, while the use of paper or computerized intravenous infusion protocols is endorsed for those critically ill. 7 Nonetheless, insulin therapy is known to increase the risk for hypoglycemia and is also often considered cumbersome and complicated, requiring frequent point of care blood glucose (BG) monitoring and intensive staff training and exposure. 8 Despite the lack of recommendations, the use of oral antidiabetic agents is a common practice in the hospital setting. Although likely effective in some patients with mild hyperglycemia, agents such as metformin and sulfonylureas should generally be avoided in acutely ill patients with contraindications or at risk for lactic acidosis or hypoglycemia. 8 

Guillermo Umpierrez, MD, CDE Emory University, Atlanta, GA, USA Key ideas • • Insulin is the preferred agent for hospital use in the management of patients with type 1 diabetes (T1D) and type 2 diabetes (T2D). • • The use of dipeptidyl peptidase-4 (DPP-4) inhibitors in medicine and surgery patients with mild-moderate hyperglycemia is safe and effective. • • Randomized controlled trials are needed to assess the inpatient efficacy and safety of other oral and injectable antidiabetics.

Summary. Although insulin is still regarded as the preferred method of glycemic control for hospitalized patients with T1D and T2D, several recent clinical studies have evaluated the safety and efficacy of the use of DPP-4 inhibitors alone or in combination with basal insulin in noncritically ill patients with lower insulin requirements (<0.6 U/(kg⊕day)) and mild to moderate hyperglycemia (<200 mg/dL). Results have consistently showed similar levels of glycemic control, compared to basal-bolus insulin regimen, but with fewer hypoglycemic events and a lower number of daily insulin injections. [9] [10] [11] Poor glycemic control has been associated with an increased risk of perioperative complications.

surrogates for glycemic control, such as fructosamine, show promise to better inform on glycemic control in the short term prior to surgery. • • Processes designed to optimize patients with diabetes at high risk of complications before surgery have shown to improve glycemic control and possibly improve outcomes. • • In terms of medication adjustments before surgery, the U.S. Food and Drug Administration (FDA) now advises that sodium-glucose cotransporter-2 (SGLT-2) inhibitors should be stopped at least three days before procedures.

Summary. Although HbA1c has been traditionally used to evaluate the level of control before surgery, new evidence suggests that short-term markers, such as fructosamine, may be better predictors of adverse outcomes after surgery. 12 Diabetes optimization programs, working in parallel or embedded within preoperative clinics, have shown to significantly improve glycemic control before surgery and reduce complications. 13, 14 Because of the risk of euglycemic diabetic ketoacidosis with the use of SGLT-2 inhibitors around surgery, the FDA recently released a labeling change, advising that these drugs should be stopped at least three days before procedures. 15 Additionally, DPP-4 inhibitors and GLP-1 agonists may have a more important role in the future perioperative management of diabetes and hyperglycemia.

Jeffrey Joseph, DO Thomas Jefferson University, Philadelphia, PA, USA Key ideas • • In the intraoperative period, the goal is to maintain the BG concentration in the desired target range for that individual (for example, 90-140 mg/dL) while minimizing the degree and duration of hyperglycemia, hypoglycemia, and glycemic variability. • • Clinicians should adjust the target BG range according to the specific physiology of each individual patient. Additional prospective randomized clinical trials are required to determine which patient populations may benefit from specific glucose targets. • • The color and quantity of urine output commonly used to inform renal perfusion or hemodynamic status may not be a reliable indicator in patients experiencing hyperglycemia.

Summary. Adequate intraoperative glycemic control has been shown to reduce complications. Ideally, glucose concentrations should be maintained within an individualized set range, while minimizing the degree and duration of hyperglycemia, hypoglycemia, and glycemic variability. 16 Anesthesiologists and surgeons identify and quantify patient risk factors prior to surgery to minimize the risk of perioperative complications. Although most recommended targets vary in between 90 and 180 mg/dL, 12 additional prospective randomized clinical trials are required to determine which patient populations may benefit from specific glucose targets. A higher than normal BG target may be appropriate for patients with diabetes experiencing decreased local blood flow due to an ischemic stroke, hemorrhagic stroke, or myocardial infarction, whereas a nearnormal BG target may be appropriate in patients undergoing cardiac surgery with satisfactory preoperative BG control. In addition, urine output may be an unreliable measure of renal perfusion during the perioperative period. In patients with significant hyperglycemia, increased urine output from glycosuria can lead to hypovolemia and acute kidney injury or renal failure in the postoperative period. 17 Summary. The most commonly identified risk factors for hyperglycemic crisis include insulin omission and infection. Alcohol use, pancreatitis, and new onset diabetes are also frequent causes. 20 Insulin omission can occur due to financial constraints, mental stress, fear of hypoglycemia, a misunderstanding about stopping insulin when ill, or a maladaptive desire to lose weight. While acute management is often protocolized, several pitfalls can be encountered during subsequent care. These include stopping the insulin infusion prior to anion gap closure, failure to overlap subcutaneous and intravenous insulin, and recurrent hyperglycemia and increased anion gap after transition. Hypoglycemia and hypokalemia are common (occurring in 12%-35% 21 and 16%-62% 22 of patients, respectively) and associated with an increase in hospital mortality. Patients are also at risk for hospital readmission and have an increase in mortality at one year. Potentially modifiable risk factors for readmission include poor glycemic control, comorbid depression, substance use and psychiatric illness, underinsurance, and homelessness. will likely require comprehensive tracking and reporting of glucometrics, as we continue to transition from a fee-for-service (volume-based) reimbursement paradigm to one that is anchored around value-based care. • • In anticipation of this requirement, and in effort to reduce cost and optimize glycemic care, AdventHealth conducted a system-wide analysis of the impact of suboptimal inpatient glycemic management on seven of its Central Florida Hospitals.

Summary. As 50% of all medication errors involve insulin, it is critical that its administration be standardized and, when continuous, automated via computerized protocols. As CMS has developed a severe hypoglycemia measure to address the issues with glycemic mismanagement, it is also essential that hospitals develop a comprehensive approach and an effective system for self-monitoring. An exhaustive analysis of 43 659 insulin-requiring patients at seven AdventHealth hospitals over 12 months revealed that, compared to patients with controlled blood sugar, those with severe hypoglycemia had a cost $10 405 more per inpatient stay ($7.7 million, total), a length of stay of 6.6 more days, a 61.5% higher readmission rate, and a threefold higher mortality rate. These findings led to the clinical implementation of several new strategies, to include personalized insulin management using an eGlycemic Management System (eGMS), defaults to basal-bolus regimens, implementation of electronic surveillance, and more aggressive training of staff around best practices. Summary. AdventHealth Waterman is a "typical" 269-bed hospital, situated in the slow-paced, lake-front town of Tavares, Florida (population 16 000, average age of 67, and 14% incidence of diabetes). As its characteristics are generalizable to many hospitals across the country, Waterman has often been utilized to pilot studies for the entire Adven-tHealth System. One of such initiative was the creation and development of a comprehensive, interdisciplinary glycemic management team, which leveraged a new eGMS and robust informatics to reduce clinical errors and improve patient safety. In addition to significantly reducing rates of severe hypoglycemia and costs ($350 000 over two years), these efforts also led to greater adherence to hospital policies, improved rates of testing for all insulin users, easier hospital-to-home transitions for patients using insulin, and a 75% reduction in new phone calls to clinicians that were related to glycemic management.

Thérèse Franco, MD, SFHM CHI Franciscan, Tacoma, WA, USA Key ideas • • Effective technology does not obviate the need for a human connection; it brings people together with easy access to the data they need for shared decision making on a personalized plan of care for the patient in front of them. • • Automation of daily dose adjustments allows providers to focus on the big picture. • • Continuous and predictive data analysis allows for more personalized care in the dynamic hospital environment.

Summary. Catholic Health Initiatives Franciscan (CHIF), located in South Puget Sound, Washington, is a system comprising eight acute care hospitals (802 beds, in aggregate) with a staff of approximately 4200 providers, 4000 nurses, and 150 pharmacists. In 2016, in response to higher rates of hypoglycemia and amid cultural and workflow barriers, CHIF leadership created a glycemic steering committee, which spearheaded an overarching glycemic management strategy. This initiative, which was anchored to a new eGMS, coordinated care by the way of order set revision, clinician education, pharmacist-led patient identification, glucometrics, and monthly process reviews. In addition to resulting in a downward trajectory for direct cost of care, these efforts led to substantial reductions in the rate of hypoglycemic events (44%, P < .001) and length of stays for both diabetic ketoacidosis and hyperglycemic hyperosmolar state patients (1.4 days, P < .001) and those with a diagnosis of diabetes (0.5 days, P < .033).

and Diabetes • • Those with diabetes and/or hyperglycemia are at increased risk for worsening complications of COVID-19 and have increased morbidity and mortality. • • Presentations of patients with severe hyperglycemia, diabetic ketoacidosis (DKA), and in some cases, severe insulin resistance (COVID and non-COVID) appear to be clinically different phenotypes and presentations than previously seen; there have also been reported changes in insulin sensitivity with infection. • • Implementing novel methods of delivery of care to decrease personal protective equipment, bundle care, and decrease face-to-face time, such as continuous glucose monitoring (CGM), is needed but may be complex to implement depending on institution resources. The Food and Drug Administration (FDA) has noted "enforcement discretion" on hospital use of CGM. • • Additional protocols that save staff time, exposure, and other resources have been planned and implemented at many hospitals at a record pace. One successful example is the use of a subcutaneous insulin protocol for mild to moderate DKA, based on the previously published work. 19 At the time of the presentation, there were no data to support that there was an increased risk of having diabetes and being at risk for getting infected with SARS-CoV2. However, there were data from China, Italy, and the United States that those with diabetes have increased morbidity and mortality once infected. 19, 23, 24 The interplay between obesity, diabetes, and glycemic control and outcomes is not clear; however, there is evidence that those with obesity and separately those with diabetes do worse clinically from COVID-19 disease. Poor glycemic control does appear to be detrimental to COVID-19-related morbidity and mortality. 25 In addition, there are clearly pathological differences in the presentations of severe hyperglycemia, DKA, and insulin resistance that are being identified and treated in the setting of the COVID-19 pandemic. These have been described in other countries, but also across the United States. These case presentations are clinically divergent from pre-COVID-19 era case descriptions and include DKA in those with pre-DM, type 2 diabetes, or no history of diabetes, and in other cases, severe insulin resistance requiring extremely high amounts of insulin. However, interestingly, some patients with previous diabetes are presenting with COVID-19 and have de-escalating diabetes medication needs, specifically much less insulin than would be typically expected. Much is still unknown about this virus and the interplay between the virus, islet cell biology, insulin sensitivity, and insulin resistance; it will be critically important to share cases, management strategies, and data between institutions so that we can learn from one another. We will also need to pay critical attention to those patients who are in minority groups and/or in socio economically disadvantaged groups.

Novel care management strategies, such as telemedicine, telehealth, and technology, have and will need to be continually adopted. Several of these strategies have been initially intended to decrease the use of PPE, and decrease potential spread of the virus to those caring for patients and to other patients in the hospital. In New York and other places, some institutions have been studying the use of CGM to reduce point of care testing and the need for face-to-face interactions with these patients. These types of strategies need to be studied, given the fact that the FDA has noted "enforcement discretion" only, and there does appear to be wide variability in the ability to implement these across institution types. Additional protocols that save staff time, exposure, and other resources have been planned and implemented at many hospitals at a record pace. One successful example is the use of a subcutaneous insulin protocol for mild to moderate DKA, based on the previously published work. 19 The FDA also released a new guidance "FAQs on Home-Use Blood Glucose Meters Utilized Within Hospitals During the COVID-19 Pandemic." 26 This allows patients to temporarily use their home BG meter during hospitalizations or allows hospitals to dispense a home meter to them, so that patients can then assist in monitoring their own BGs during hospitalizations. This plan could be utilized at a time of nursing, staff, or lab constraints during a surge.

Everyone can agree that the advent of COVID-19 has changed diabetes healthcare delivery in the hospital, and we need to continue to come together to combat this virus and make more of the unknown, known. , support the use of insulin pumps in the hospital. The organizations recommend institutional policy and procedures for CSII use, pump order sets, a signed agreement with the patient, personnel familiar with CSII therapy, and criteria for proper patient selection. Insulin pumps can also be used safely in the perioperative setting if defined decision-making processes are used and clearly outlined care process models (including provisions for transitions of care) are in place. 29 Closed-loop and DIY systems are also becoming more common in the inpatient setting, but are best used in manual mode in the hospital because of the current limitations of technology in the inpatient setting. Summary. Despite over two decades of extensive work creating infrastructure such as order sets, work flows, and education on inpatient diabetes management with improved glucometrics and low rates of hypoglycemia, audits continued to show inappropriate initial insulin orders and clinical inertia for both attending staff and house staff at UCSF. With the implementation of electronic health record and creation of daily reports identifying patients in real time who were out of control, the vGMS was established and could provide clinicians with appropriate glucose management recommendations in a timely manner via a brief note in the chart and just-in-time education. 30 Through these efforts, there was a significant decrease in hospital-wide hyperglycemia and hypoglycemia. 31 The next steps are to expand vGMS to local affiliated hospitals, apply artificial intelligence to vGMS, and learn from patients and experience to make fundamental changes in the inpatient glucose management system.

Kristen Kulasa, MD UCSD, La Jolla, CA, USA Key ideas • • Computer-guided intravenous (IV) insulin infusion has higher staff satisfaction, better compliance with protocol, more time with glucose in range, and less variability than typical paper protocols. • • UC San Diego Health has been using a "home-grown" computerized insulin infusion protocol since 2004 and successfully integrated the algorithm directly into the EPIC medication administration record (MAR) in 2017 with safety and efficacy data comparable to published and commercial products. • • Computer-guided subcutaneous insulin dosing is also available using standardized order sets with built-in clinical decision support, commercial products with full basal, bolus insulin dosing, or "home-grown" options such as UC San Francisco's subcutaneous insulin calculator for continuous nutrition.

Summary. Computer-guided IV insulin infusion has higher staff satisfaction, better compliance with protocol, more time with glucose in range, and less variability than typical paper protocols. UC San Diego Health has been using a "home-grown" computerized insulin infusion protocol since 2004 and successfully integrated the algorithm directly into the EPIC MAR in 2017 with safety and efficacy data comparable to the published commercial products. This computerized insulin infusion calculator is used in a variety of hospital and clinical settings, including ICU, non-ICU, emergency department, hyperglycemic emergencies, diabetes in pregnancy, and patients with renal failure. Computerguided subcutaneous insulin dosing is also available using standardized order sets with built-in clinical decision support, commercial products with full basal, bolus insulin dosing, or "home-grown" options such as UC San Francisco's subcutaneous insulin calculator for continuous nutrition. Leveraging technology to improve adherence to protocols, provide clinical decision support, and assist with both IV and subcutaneous insulin dosing is possible and is becoming increasingly more common. Key ideas • • Hypoglycemic agents account for over half of adverse drug events in hospitalized patients. Iatrogenic hypoglycemia in the hospital has been associated with cardiac and neurologic symptoms, increased costs, longer length of stay, increased nursing resources, and mortality. • • Real-time alerting of patients at high risk of near-term iatrogenic hypoglycemia has the potential to reduce rates of this potentially serious adverse event. Early prediction models of iatrogenic hypoglycemia in the hospital setting had poor predictive accuracy owing to the small sample sizes and limited number of clinical predictors. Machine learning methods using very large electronic medical record (EMR) datasets can substantially improve the predictive accuracy of iatrogenic hypoglycemia models. Recent machine learning prediction models, while highly accurate, have used a prediction horizon of the entire admission, which limits the ability to translate such models into real-time informatics alerting to modify prescribing practices of hypoglycemic medications throughout the course of a patient's hospitalization. Prediction models using a shorter prediction horizon (e.g. next 24 hours) would offer greater value to inpatient clinicians considering that antihyperglycemic medications are typically adjusted on a daily basis. • • Machine learning prediction models integrated into the EMR for reducing the incidence of iatrogenic hypoglycemia should be validated both internally and externally to assess their generalizability across different patient populations and health systems.

Summary. A significant proportion of inpatients have diabetes or hypoglycemia and almost two million hospital stays annually in the US are affected by adverse drug events caused by hypoglycemic agents. Iatrogenic hospital hypoglycemia increases the risk of poor clinical outcomes as well as costs and resources needed. An iatrogenic hypoglycemia prediction model (using machine learning) integrated with a patient's EMR could provide real-time alerts to healthcare professionals. Using a shorter prediction horizon would also help with providing useful real-time predictive data. Timely notification would allow healthcare professionals to predict or treat iatrogenic hypoglycemia at an early stage. Such notifications could inform a clinical strategy based on a patient's current medications and preferences. Validating a prediction model using both internal and external EMR data sets is necessary to assess generalizability of the model and to allow for implementation of the model in multiple hospitals. Summary. Common sources of insulin errors in the hospital setting are dose omission, overdosage, and underdosage. 33 These errors can lead to dysglycemia and poor outcomes. The ECRI and its affiliate, ISMP, are working together to educate healthcare professionals on unsafe conditions in the hospital and possible strategies for prevention; they advocate for improvements in drug labeling, packaging, and processing because many insulin errors result from drug packaging and names that look similar. Creating alerts in the EHR that remind prescribers to order basal insulin for patients with T1D could lead to a decreased number of insulin errors since these errors often occur because of prescriber, nurse, or pharmacy errors. Healthcare professionals should also be informed of the value of comprehensive weight-and sensitivity-based insulin order sets to promote sensible insulin dosing. Summary. Cybersecurity is the protection of connected medical devices from unauthorized disclosure, modification, and loss of function. Sound cybersecurity protects confidentiality integrity and availability of data. Cybersecurity is one feature of a connected medical device, in addition to safety, effectiveness, privacy, usability, and cost. Wearable and hospital devices contain personal, medical, and financial information about patients that can be targets for hackers. No patient harm has been reported through a cybersecurity breach of a diabetes device. The Food and Drug Administration (FDA) regulates device cybersecurity and requires demonstration of robust cybersecurity for wireless device clearance. The FDA does not test devices for cybersecurity. Therefore, meeting standards for cybersecurity, like the Diabetes Technology Society (DTS) Cybersecurity Standard for Connected Diabetes Devices, provides a path for a manufacturer to provide assurance to patients and healthcare professionals about the safety of wireless diabetes devices. Hospitals are vulnerable to security breaches because they often use outdated operating systems in an unpartitioned network and they may lack the resources to address cyber threats.

Tonya Newman, JD Neal, Gerber & Eisenberg LLP, Chicago, IL, USA Key ideas • • To the extent feasible, expanding the indications for CGM into appropriate inpatient settings has been advocated. • • The question of whether to seek FDA approval, whether to share any Software as a Medical Device (SaMD), and the associated potential exposures should be carefully considered and discussed with the hospital's counsel and risk management team, to ensure that the hospital's potential exposures are minimized to the greatest extent possible. • • If hospitals are going to develop their own software systems to store and summarize the data from continuous glucose monitors, then consider collaborative working groups to ensure that all potential exposures are being considered and appropriate expertise is available to mitigate those risks

Summary. The FDA likely would consider an insulin dosing system to be an SaMD, and any hospital developing and sharing such a system probably should first seek FDA approval and otherwise comply with the applicable regulatory requirements. Similarly, software functions using an attachment to the mobile platform to measure glucose levels are subject to regulatory oversight rather than discretion. Failure to obtain FDA approval could (and likely would) also be used against a hospital defendant in malpractice and other litigation. Developing and sharing SaMD should proceed only after the associated potential exposures have been carefully considered and discussed with the hospital's counsel and risk management team, to ensure that the hospital's potential exposures are minimized to the greatest extent possible.

Moderator • • Factors to consider when managing steroid-induced hyperglycemia include history of type 1 or type 2 diabetes, eating status, and steroid factors, such as the type of GC, dose, and dosing schedule.

Summary. Hyperglycemia can often occur in patients receiving GCs, regardless of whether or not they have a history of diabetes. Glucocorticoids can cause hyperglycemia through a decrease in pancreatic insulin secretion, an increase in hepatic gluconeogenesis, a decrease in insulin sensitivity, or an impairment of the incretin effect. The correlation between GC usage with the degree of blood glucose elevation is unclear, because patients have different diabetes histories and often receive different GC formulations, doses, and dosing schedules, leading to varying hyperglycemic effects. All of these factors must be considered when managing steroidinduced hyperglycemia. Glucose monitoring is recommended for patients on GCs, especially those with diabetes or a history of diabetes. NPH (Neutral Protamine Hagedorn) insulin, basal-bolus insulin, or modified basal-bolus insulin therapy can be used to manage hyperglycemia in patients with preexisting diabetes. 34 There are limited data on the effects of oral agents and non-insulin injectables on steroidinduced hyperglycemia. to be evaluated on a case-by case basis, as dose adjustment for renal function, side effect profiles, drug-drug interactions, and potential comorbidities need to be taken into account in this specialized population.

Summary. After receiving a transplant, patients who experience hyperglycemia can be at an increased risk for transplant rejection because of increased inflammation and endothelial dysfunction. 36, 37 Many medications, such as corticosteroids and calcineurin inhibitors, used for immunosuppression to reduce risk of transplant rejection and induce hyperglycemia through multiple mechanisms, increasing the probability of poor clinical outcome. Using insulin may alleviate symptoms associated with hyperglycemia in the short term because of its regulatory effect on inflammation and immunity. The dose of insulin can be decreased as estimated glomerular filtration rate approaches 45 mL/ min to maintain glycemic control and reduce the risk of hypoglycemia. Further studies on noninsulin treatment options such as oral or injectable medications need to be done to compare the effectiveness in both short-term and long-term outcomes and to assess potential comorbidities and side effects. Coronavirus disease 2019 patients with diabetes or hyperglycemia were characterized with recurrent uncontrolled hyperglycemia and an increased mortality rate. 38 

Erik Dutson, MD, FACS UCLA, Los Angeles, CA, USA Key ideas • • There is now sufficient clinical and mechanistic evidence to support the inclusion of metabolic surgery among the antidiabetes interventions for people with type 2 diabetes (T2D) and obesity. • • For morbidly obese patients with T2D, not having surgery is much more dangerous than having surgery in the long term. • • Bariatric surgeons and endocrinologists can and should work together to help these patients.

Summary. Obesity trends mirror diabetes trends in U.S. adults and obesity has surpassed tobacco use as the number one cause of preventable death. Obesity is a major risk factor for developing T2D, and the probability of attaining a normal body weight for an obese person is very low with diet and exercise alone. 39 Over 90% of patients with T2D are overweight. Bariatric surgery is rapidly emerging as an antidiabetes intervention for T2D and obesity because of decreases in the severity of symptoms and low recurrence rates after the procedure. After treatment, the ghrelin signaling pathway is disrupted, decreasing the patient's appetite and effectively helping the patient lose weight. Studies have shown that weight loss corresponds with better clinical outcomes and reduced recurrence rates after bariatric surgery. Future collaboration between bariatric surgeons and endocrinologists is necessary to ensure optimal patient care. Summary. Insulinometrics is the systematic analysis and reporting of inpatient insulin therapy. Insulin therapy is needed for most patients with diabetes and hyperglycemia in order to achieve recommended glucose goals. Yet the clinical inertia, defined as a failure to appropriately intensify insulin therapy, continues to be a barrier limiting the achievement of these goals. It is in part rooted in practitioners' discomfort when prescribing insulin, which is recognized as a high-risk medication with a potential to cause significant harm when used in error. Therefore, analysis and understanding of insulin use and choice of therapy may guide institutions' efforts to overcome clinical inertia. Identifying areas with a high rate of hypo-or hyperglycemia can trigger the analysis of how insulin is used. Given its high-risk classification, tracking insulin errors should be a top insulinometric. Insulin errors can be classified as wrong dose, wrong insulin, and whether or not the error reached the patient. Control charts can be developed to track details of insulin errors. Institutions can also track the number of insulin orders written and doses delivered. They can then analyze whether or how insulin therapy is being modified. Measuring patterns of insulin therapy against some type of glucometric may identify an opportunity to shift from correction-dosing to basal-bolus therapy. Glucometrics and insulinometrics should be utilized together to assess an institution's management of glucose control and facilitate the achievement of goals. Summary. There is a growing understanding of the interaction between food and medicine in the hospital setting. The inpatient administration of rapid-acting nutritional insulin may not match the timing of a meal, thus leading to hypoglycemia or hyperglycemia. Smart insulin pens are becoming more available and can log the timing and dose of insulin given. A recent study describing the use of smart insulin pens with memory and continuous glucose monitoring systems has shown that around 27% of boluses are late or missed completely. These pens may have the potential to reduce in-hospital insulin errors. Furthermore, layering decision support tools in the noncritical care hospital setting may also lead to improvements in glucose control, better clinical outcomes, and variations in the length of stay across hospitals and financial benefits. The incidences of diabetes and obesity continue to rise. Given the known association between diabetes and obesity and the risk of adverse events in hospitals, more attention should be given to optimizing lifestyle interventions, especially food choices before hospital admission to reduce individual risk.

Gregory Maynard, MD, MSc, MHM UC Davis, Sacramento, CA, USA Key ideas • • Quality improvement may improve health and reduce the cost of care. • • Following a roadmap for improvement, without skipping essential steps, may improve the chances of success of a quality improvement project. • • Plotting data over time may show progress visually and may help to avoid errors in interpreting common "before and after" analyses.

Summary. Quality improvement activities are essential to improving the health of the population, enhancing patient experiences and outcomes, and reducing the cost of care. However, about 80% of quality improvement projects fail to reach their stated objectives. Healthcare organizations can dramatically improve their chances of success by following a roadmap for improvement, without skipping essential steps. Defining the problem is the first and most important step. Process mapping, brainstorming, Pareto charts, and Fishbone diagrams may help identify key drivers of dysfunction in a system and thus generate interventions that address those key drivers. Plotting data over time in annotated run charts or statistical process control charts show progress visually and avoid errors in interpreting common "before and after" analyses. The COVID-19 crisis may decrease the funding of quality improvement hospital-based projects.

Roma Gianchandani, MD University of Michigan, Ann Arbor, MI, USA Key ideas • • Various specialized diabetes team models may be one of the best ways to manage diabetes in hospitalized patients. • • These initiatives may help reduce hospital readmissions and the length of stay of patients with diabetes. • • Hospital diabetes management programs may lead to better outcomes and financial savings for the hospital.

Summary. Different formats of diabetes management teams may include solo endocrine consultants, multidisciplinary and/or virtual consulting teams. Advanced practice providers are frequently utilized to take care of hospitalized patients with diabetes. Other members of the team may include residents, Endocrinology fellows, diabetes educators, nutritionists, pharmacists, case managers, and social workers. There is no single best program format, as every institution may have different needs and resources. An "automatic consult concept" may be useful in some of the medical units, which helps to avoid the delay of care of patients with diabetes. Specialized diabetes teams may help reduce hospital readmissions and the length of stay of patients with diabetes, especially if they are involved in diabetes care early in the admission. Hospital diabetes management programs may lead to better outcomes and financial savings for the hospital. Summary. Endocrine Hospitalist is the new field of endocrinology, modeled after the general hospitalist service. It was designed to improve the quality of diabetes care in hospitalized patients. Because of its "make-whole" design, it requires an upfront financial investment from a hospital. The Hospital Readmissions Reduction Program is a Medicare value-based purchasing program that reduces payments to hospitals with excess readmissions. The readmission data for every hospital in the United States are available in the public domain and hospitals take pride in readmission reduction. The Endocrine Hospitalist model has proven its worth in reducing lengths of stay, hospital readmissions, and inpatient hypoglycemia, and providing a significant return on investment. 40, 41 Inpatient diabetes telehealth approach may be reasonable for some hospitalized patients with COVID-19 and dysglycemia. 42 The Endocrine Hospitalist model should guide other community hospitals in their endocrine and glucose management initiatives. 43

The Hospital Diabetes Meeting's sessions provided a comprehensive overview of different areas related to the inpatient management of diabetes. This event outlined the advances of diabetes technology in the hospital setting. Based on the rapid progress in this area, it is reasonable to anticipate increasing demand for the use of these technological approaches that will be dictated by hospital administrators, healthcare professionals, and/or patients with diabetes. This report provides important and novel information about how to improve the health care of hospitalized patients with diabetes without increasing the liability risk or compromising safety, privacy, or cybersecurity.

Centers for Disease and Control and Prevention; CGM, continuous glucose monitoring; CHIF, Catholic Health Initiatives Franciscan; CMS

CSII, continuous subcutaneous insulin infusion

DIY, doit-yourself

Diabetes Technology Society; ECRI, Emergency Care Research Institute

ED, emergency department; eGMS, eGlycemic Management System®

EHR, electronic health record; EMR, electronic medical record; EN, enteral; FDA, United States Food and Drug Administration

HHS, hyperglycemic hyperosmolar syndrome

intensive care unit; IDEA, insulin dose error assessment

Institute for Safe Medication Practices

IV, intravenous; MAR, medication administration record

MARD, mean absolute relative difference; NHSN, National Healthcare Safety Network; NPH, Neutral Protamine Hagedorn

National Quality Forum; PN, parenteral; POC, point of care

PPE, personal protective equipment; SaMD, Software as a Medical Device

T1D, type 1 diabetes

Declaration of Conflicting Interests The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Guillermo Umpierrez is the editor-in-chief for BMJ Open Diabetes Research & Care. He has received research funding from Sanofi, Novo Nordisk

He serves as a speaker or as a member of a speakers' bureau for GLYTEC. Amisha Wallia has received research funding from Novo Nordisk and research support from Eli Lilly and the UnitedHealth Group. Mihail Zilbermint is a consultant for Guidepoint

Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline

Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes

Increased glycemic variability is independently associated with length of stay and mortality in noncritically ill hospitalized patients

Association of glucose concentrations at hospital discharge with readmissions and mortality: a nationwide cohort study

Economic costs of diabetes in the U.S

Diabetes care in the hospital: standards of medical care in diabetes-2020

Inpatient management of T2DM and hyperglycemia in older adults

Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial

Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients

A randomized controlled study comparing a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in patients with type 2 diabetes in long-term care and skilled nursing facilities: linagliptin-LTC trial

John Insall Award: Fructosamine is a better glycaemic marker compared with glycated haemoglobin (HbA1c) in predicting adverse outcomes following total knee arthroplasty: a prospective multicentre study

Preoperative diabetes optimization program

Effect of preoperative diabetes management on glycemic control and clinical outcomes after elective surgery

FDA approves label changes to SGLT2 inhibitors regarding temporary discontinuation of medication before scheduled surgery

Poor intraoperative blood glucose control is associated with a worsened hospital outcome after cardiac surgery in diabetic patients

Hyperglycemia and acute kidney injury during the perioperative period

Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia

Treatment of diabetic ketoacidosis with subcutaneous insulin aspart

Incidence and long-term outcomes of critically ill adult patients with moderate-to-severe diabetic ketoacidosis: retrospective matched cohort study

Comparison of computer-guided versus standard insulin infusion regimens in patients with diabetic ketoacidosis

Trends in emergency department visits and inpatient admissions for hyperglycemic crises in adults with diabetes in the

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)

Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States

FAQs on Home-use blood glucose meters utilized within hospitals during the COVID-19 pandemic

T1D Exchange Clinic Network. State of type 1 diabetes management and outcomes from the T1D exchange in 2016

Temporal trends and contemporary use of insulin pump therapy and glucose monitoring among children, adolescents, and adults with type 1 diabetes between

Diabetes technology update: use of insulin pumps and continuous glucose monitoring in the hospital

A detailed description of the implementation of inpatient insulin orders with a commercial electronic health record system

Association between a virtual glucose management service and glycemic control in hospitalized adult patients: an observational study

with or without insulin therapy, is associated with increased mortality among hospitalized patients

Medication errors with the dosing of insulin: problems across the continuum. Pa Patient Saf Advis

Steroid-associated hyperglycemia

Differences in glycemic control in diabetic and non-diabetic patients with parenteral nutrition using a basal plus correction insulin regimen: an observational, retrospective study

Intensive insulin therapy protects the endothelium of critically ill patients

Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States

Treating obesity seriously: when recommendations for lifestyle change confront biological adaptations

Retrospective study of inpatient diabetes management service, length of stay and 30-day readmission rate of patients with diabetes at a community hospital

Building a business case for inpatient diabetes management teams: lessons from our center

Inpatient diabetes management during the COVID-19 crisis: experiences from two community hospitals

In the house: how inpatient diabetes teams can improve patient outcomes and reduce costs

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Elias K. Spanakis https://orcid.org/0000-0002-9352-7172Mihail Zilbermint https://orcid.org/0000-0003-4047-7260David C. Klonoff https://orcid.org/0000-0002-0624-698X